Actively Recruiting
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Led by West China Hospital · Updated on 2025-11-24
10
Participants Needed
1
Research Sites
144 weeks
Total Duration
On this page
Sponsors
W
West China Hospital
Lead Sponsor
G
GV20 Therapeutics
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.
CONDITIONS
Official Title
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign informed consent before any study procedures
- Willing and able to participate throughout the entire study and follow procedures
- Aged 18 years or older
- Have a histologically confirmed advanced solid tumor with progressive disease requiring therapy
- Refractory or intolerant to standard therapies and must have received standard care
- ECOG performance status of 0 or 1 before first treatment day
- Disease-free of active second or prior malignancies for at least 2 years
- Laboratory test results within required ranges
- Women of childbearing potential and men must agree to use effective contraception
You will not qualify if you...
- Diagnosis of acute leukemia or chronic lymphocytic leukemia
- History of heart disease, myocardial infarction within 6 months, or unstable arrhythmia
- QTcF interval greater than 470 msec or congenital long QT syndrome or significant ECG abnormalities
- Active uncontrolled infections requiring systemic therapy within 7 days of first treatment
- Active autoimmune disease or requiring chronic steroid or immunosuppressive therapy
- Known HIV, hepatitis B, or hepatitis C infection unless specific conditions are met
- History of major organ or bone marrow transplant
- Symptomatic central nervous system malignancy or metastasis
- Serious nonmalignant disease
- Pregnant or nursing women
- Major surgery within 28 days before first dose
- Prior anticancer therapy within 4 weeks or 5 half-lives before first dose (exceptions apply)
- History of severe allergic reactions to biologic therapy
- Radiation therapy for symptomatic lesions within 14 days before first dose
- Active substance abuse
- History of immune-related grade 3 or higher adverse events from prior cancer immunotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital
Chengdu, Sichuan, China
Actively Recruiting
Research Team
J
Jin Zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here